AR078950A1 - Peptido agonista de la guanilato ciclasa c (gc-c) util para tratamientos de trastornos gastrointestinales - Google Patents
Peptido agonista de la guanilato ciclasa c (gc-c) util para tratamientos de trastornos gastrointestinalesInfo
- Publication number
- AR078950A1 AR078950A1 ARP100104153A ARP100104153A AR078950A1 AR 078950 A1 AR078950 A1 AR 078950A1 AR P100104153 A ARP100104153 A AR P100104153A AR P100104153 A ARP100104153 A AR P100104153A AR 078950 A1 AR078950 A1 AR 078950A1
- Authority
- AR
- Argentina
- Prior art keywords
- acid
- cys
- asp
- glu
- carboxylated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Nutrition Science (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Neurology (AREA)
Abstract
La presente también provee composiciones y métodos para tratar trastornos gastrointestinales y composiciones farmacéuticas para llevar a cabo dicho métodos. En algunas formas de realizacion, estas composiciones farmacéuticas incluyen formas de dosis orales. Reivindicacion 1: Un péptido o una sal farmacéuticamente aceptable del mismo, en donde el péptido comprende la secuencia de aminoácidos Xaa1 Xaa2 Xaa3 Xaa4 Cys5 Xaa6 Xaa7 Xaa8 Cys9 Asn10 Pro11 Ala12 Cys13 Xaa14 Gly15 Xaa16 Xaa17, o una sal farmacéuticamente aceptable de los mismos; en donde Xaa1 es Asn, D-Asn, Gln, D-Gln, Pro, Ala, Beta-Ala, D-Ala, Val, D-Val, Gly, Thr, D-Thr, Asp, D-Asp, Asp Gama-carboxilado, Glu, D-Glu, Glu Gama-carboxilado, ácido alfa-aminosubérico (Asu), ácido alfa-aminoadípico (Aad), ácido alfa-aminopimélico (Apm), o se halla ausente; Xaa2 es Asp, Asp Gama-carboxilado, Glu, Glu Gama-carboxilado, Asu, Aad, Apm, o se halla ausente; Xaa3 es Asp, Asp Gama-carboxilado, Glu, Glu Gama-carboxilado, Asu, Aad, Apm, o se halla ausente; Xaa4 es Cys o D-Cys; Xaa6 es P-Ser, P-Thr, P-homo-Ser, fosfato de 4-hidroxivalina, P-homo-Thr, P-Cys o P-Tyr; Xaa7 es Tyr, Leu, Phe o Ile; Xaa8 es Cys o D-Cys; Xaa14 es Thr, Ala o Phe; Xaa16 es Cys o D-Cys; y Xaa17 es Tyr, D-Tyr, o se halla ausente; en donde: si Xaa1 se halla presente, Xaa1 puede ser modificado sobre su grupo amino por metilo, ácido etanodioico, ácido propanodioico, ácido butanodioico, ácido pentanodioico, ácido hexanodioico, ácido heptanodioico o ácido octanodioico; si Xaa1 se hallaba ausente y Xaa2 se halla presente, entonces Xaa2 puede ser modificado sobre su grupo amino por metilo, ácido etanodioico, ácido propanodioico, ácido butanodioico, ácido pentanodioico, ácido hexanodioico, ácido heptanodioico o ácido octanodioico; o si tanto Xaa1 como Xaa2 están ausentes, entonces Xaa3 puede ser modificado sobre su grupo amino por metilo, ácido etanodioico, ácido propanodioico, ácido butanodioico, ácido pentanodioico, ácido hexanodioico, ácido heptanodioico o ácido octanodioico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25926409P | 2009-11-09 | 2009-11-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078950A1 true AR078950A1 (es) | 2011-12-14 |
Family
ID=43503086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100104153A AR078950A1 (es) | 2009-11-09 | 2010-11-09 | Peptido agonista de la guanilato ciclasa c (gc-c) util para tratamientos de trastornos gastrointestinales |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US8507447B2 (es) |
| EP (1) | EP2499154B1 (es) |
| JP (1) | JP5913115B2 (es) |
| KR (1) | KR20120115495A (es) |
| CN (1) | CN102812038B (es) |
| AR (1) | AR078950A1 (es) |
| AU (1) | AU2010314866B2 (es) |
| BR (1) | BR112012011730A2 (es) |
| CA (1) | CA2779482A1 (es) |
| CL (1) | CL2012001186A1 (es) |
| CO (1) | CO6551683A2 (es) |
| CR (1) | CR20120303A (es) |
| EA (1) | EA022817B1 (es) |
| EC (1) | ECSP12011962A (es) |
| ES (1) | ES2620153T3 (es) |
| GE (1) | GEP20166435B (es) |
| IL (1) | IL219596A0 (es) |
| MX (2) | MX350046B (es) |
| NZ (1) | NZ599751A (es) |
| PH (1) | PH12012500916B1 (es) |
| SG (1) | SG10201407403UA (es) |
| TW (1) | TWI482626B (es) |
| UA (1) | UA114274C2 (es) |
| UY (2) | UY33018A (es) |
| WO (1) | WO2011057272A1 (es) |
| ZA (1) | ZA201203342B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2170930B3 (en) | 2007-06-04 | 2013-10-02 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| JP2011522828A (ja) | 2008-06-04 | 2011-08-04 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
| EP2321341B1 (en) | 2008-07-16 | 2017-02-22 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| WO2010065524A2 (en) * | 2008-12-02 | 2010-06-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of fluid retention disorders |
| AU2010314866B2 (en) * | 2009-11-09 | 2014-10-30 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
| US8735360B2 (en) * | 2009-12-07 | 2014-05-27 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
| CA2835624A1 (en) | 2011-05-11 | 2012-11-15 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
| WO2012155114A1 (en) | 2011-05-11 | 2012-11-15 | Ironwood Pharmaceuticals, Inc. | Peptides derived from uroguanylin and their use in gastrointestinal disorders |
| WO2012155108A1 (en) * | 2011-05-11 | 2012-11-15 | Ironwood Pharmaceuticals, Inc. | Treatments for disorders using guanylate cyclase c agonists |
| US9617305B2 (en) | 2011-06-08 | 2017-04-11 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
| US9527887B2 (en) | 2011-06-08 | 2016-12-27 | Ironwood Pharmaceutical, Inc. | Treatments for gastrointestinal disorders |
| DK2776055T3 (en) * | 2011-08-17 | 2017-03-06 | Ironwood Pharmaceuticals Inc | TREATMENTS FOR GASTROINTESTINAL DISORDERS |
| WO2014088623A1 (en) * | 2012-07-12 | 2014-06-12 | Forest Laboratories Holdings Limited | Linaclotide compositions |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| CN114404588A (zh) | 2013-08-09 | 2022-04-29 | 阿德利克斯公司 | 用于抑制磷酸盐转运的化合物和方法 |
| AU2014331812B2 (en) * | 2013-10-09 | 2019-01-17 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines |
| WO2016015055A1 (en) * | 2014-07-25 | 2016-01-28 | Ironwood Pharmaceuticals, Inc. | Colon cleansing compositions |
| WO2020237096A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Combination for lowering serum phosphate in a patient |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB290795A (en) | 1927-04-08 | 1928-05-24 | British Colour Printing Compan | Improvements in or relating to advertising or display devices |
| ES2216004T3 (es) * | 1993-10-26 | 2004-10-16 | Thomas Jefferson University | Composiciones que se unen especificamente a celulas cancerosas colorectales y procedimientos de uso de las mismas. |
| US5962220A (en) * | 1993-10-26 | 1999-10-05 | Thomas Jefferson University | Compositions that specifically bind to colorectal cells and methods of using the same |
| US5601990A (en) * | 1994-09-13 | 1997-02-11 | Thomas Jefferson University | Methods of diagnosing colorectal tumors and metastasis thereof |
| US5518888A (en) * | 1993-10-26 | 1996-05-21 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
| US5879656A (en) * | 1993-10-26 | 1999-03-09 | Thomas Jefferson University | Methods of treating metastatic colorectal cancer with ST receptor binding compounds |
| CH689139A5 (de) | 1995-04-03 | 1998-10-30 | Cerbios Pharma Sa | Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung. |
| US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
| AU2001256315A1 (en) * | 2000-04-22 | 2001-11-07 | Ipf Pharmaceuticals Gmbh | Use of guanylate cyclase-c (gc-c) agonists as insulinotropic factors for treating diabetes type 2 |
| US7371727B2 (en) * | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2004069165A2 (en) * | 2003-01-28 | 2004-08-19 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7304036B2 (en) * | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7772188B2 (en) * | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US20090253634A1 (en) * | 2005-08-19 | 2009-10-08 | Microbia, Inc. | Methods and Compositions for the Treatment of Gastrointestinal Disorders |
| EP2170930B3 (en) * | 2007-06-04 | 2013-10-02 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| PT2328601T (pt) * | 2008-08-15 | 2020-04-30 | Ironwood Pharmaceuticals Inc | Formulação sólida estável de um polipéptido agonista do recetor gc-c adequado para administração oral |
| WO2010027405A2 (en) * | 2008-09-04 | 2010-03-11 | Ironwood Pharmaceuticals, Inc. | Stable solid formulations of gc-c receptor agonist polypeptides suitable for oral administration |
| AU2010314866B2 (en) * | 2009-11-09 | 2014-10-30 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
| WO2011156453A2 (en) | 2010-06-09 | 2011-12-15 | Combimab, Inc. | Therapeutic peptides |
-
2010
- 2010-11-09 AU AU2010314866A patent/AU2010314866B2/en not_active Ceased
- 2010-11-09 WO PCT/US2010/056042 patent/WO2011057272A1/en not_active Ceased
- 2010-11-09 TW TW099138547A patent/TWI482626B/zh not_active IP Right Cessation
- 2010-11-09 JP JP2012538087A patent/JP5913115B2/ja not_active Expired - Fee Related
- 2010-11-09 MX MX2014016035A patent/MX350046B/es unknown
- 2010-11-09 AR ARP100104153A patent/AR078950A1/es unknown
- 2010-11-09 EA EA201290322A patent/EA022817B1/ru not_active IP Right Cessation
- 2010-11-09 BR BR112012011730A patent/BR112012011730A2/pt not_active IP Right Cessation
- 2010-11-09 CA CA2779482A patent/CA2779482A1/en not_active Abandoned
- 2010-11-09 GE GEAP201012738A patent/GEP20166435B/en unknown
- 2010-11-09 PH PH1/2012/500916A patent/PH12012500916B1/en unknown
- 2010-11-09 UA UAA201206987A patent/UA114274C2/uk unknown
- 2010-11-09 US US12/942,887 patent/US8507447B2/en active Active
- 2010-11-09 NZ NZ599751A patent/NZ599751A/en not_active IP Right Cessation
- 2010-11-09 CN CN201080060997.XA patent/CN102812038B/zh not_active Expired - Fee Related
- 2010-11-09 SG SG10201407403UA patent/SG10201407403UA/en unknown
- 2010-11-09 EP EP10782095.3A patent/EP2499154B1/en active Active
- 2010-11-09 ES ES10782095.3T patent/ES2620153T3/es active Active
- 2010-11-09 KR KR1020127014811A patent/KR20120115495A/ko not_active Abandoned
- 2010-11-09 UY UY0001033018A patent/UY33018A/es not_active Application Discontinuation
- 2010-11-09 UY UY0001033017A patent/UY33017A/es not_active Application Discontinuation
- 2010-11-09 MX MX2012005368A patent/MX2012005368A/es active IP Right Grant
- 2010-11-09 US US13/508,843 patent/US20140179607A9/en not_active Abandoned
-
2012
- 2012-05-03 IL IL219596A patent/IL219596A0/en unknown
- 2012-05-07 ZA ZA2012/03342A patent/ZA201203342B/en unknown
- 2012-05-07 CL CL2012001186A patent/CL2012001186A1/es unknown
- 2012-05-16 CO CO12081055A patent/CO6551683A2/es active IP Right Grant
- 2012-06-06 CR CR20120303A patent/CR20120303A/es unknown
- 2012-06-08 EC ECSP12011962 patent/ECSP12011962A/es unknown
-
2013
- 2013-03-14 US US13/830,656 patent/US8946158B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR078950A1 (es) | Peptido agonista de la guanilato ciclasa c (gc-c) util para tratamientos de trastornos gastrointestinales | |
| Raizada et al. | ACE2: a new target for cardiovascular disease therapeutics | |
| Mercer et al. | Peptides as the next generation of anti-infectives | |
| CY1124910T1 (el) | Μεθοδοι και συνθεσεις για παραδοση στο κνς της αρυλοσουλφατασης α | |
| MX2019013628A (es) | Formulaciones que contienen linaclotida para administracion oral. | |
| CO6260151A2 (es) | Peptido de cdh3 y agente medicinal que comprende al mismo | |
| US10363282B2 (en) | Analogs of C5a and methods of using same | |
| PE20130579A1 (es) | Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa | |
| HRP20110242T1 (hr) | Formulacija s fuzijskim proteinom glp-1-fc | |
| AU2018205186B2 (en) | Angiotensin in treating brain conditions | |
| AR060487A1 (es) | Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40 | |
| CA2697504A1 (en) | Salicylanilide modified peptides for use as oral therapeutics | |
| AR068020A1 (es) | Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico | |
| AU2019314383A1 (en) | Engineered hemichannels, engineered vesicles, and uses thereof | |
| HRP20161560T1 (hr) | Varijanta, rekombinantnih proteina beta-glukocerebrozidaze s povećanom stabilnošću i povećanom zadržanom katalitičkom aktivnošću | |
| RU2013146690A (ru) | Циклические пептиды с антинеопластической и антиангионенной активностью | |
| AR073810A1 (es) | Polipeptidos que tienen actividad antimicrobiana | |
| CA3073062A1 (en) | Tau aggregation peptide inhibitors | |
| AR064269A1 (es) | Formulaciones inhalantes de bisfosfonato y metodos para su utilizacion | |
| CA2912635A1 (en) | Angiotensin peptides in treating marfan syndrome and related disorders | |
| CN105636645A (zh) | 在肌萎缩症中的血管紧张素 | |
| CA2940751A1 (en) | Uses of an angiotensin (1-7) peptide for the delayed treatment of stroke | |
| AR087727A1 (es) | Analogos del factor de liberacion de la hormona de crecimiento (grf) y sus usos | |
| Barreto et al. | Octreotide negates the benefit of galantide when used in the treatment of caerulein-induced acute pancreatitis in mice | |
| AU2013215269A1 (en) | Beta-arrestin effectors and compositions and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |